PureTech Health PLC
PRTC19.000USD
-0.089-0.47%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
4.55BCap. mercado
--P/E TTM
Más Datos de PureTech Health PLC Compañía
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.
Información de la empresa
Símbolo de cotizaciónPRTC
Nombre de la empresaPureTech Health PLC
Fecha de salida a bolsaJun 19, 2015
Director ejecutivoMr. Robert (Rob) Lyne
Número de empleados56
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 19
Dirección6 Tide Street
CiudadBOSTON
Bolsa de valoresLondon Stock Exchange
PaísUnited States of America
Código postal02210
Teléfono16174822333
Sitio Webhttps://puretechhealth.com/
Símbolo de cotizaciónPRTC
Fecha de salida a bolsaJun 19, 2015
Director ejecutivoMr. Robert (Rob) Lyne
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kiran Mazumdar-Shaw
Ms. Kiran Mazumdar-Shaw
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sharon Barber-lui
Ms. Sharon Barber-lui
Interim Independent Non-Executive Chairman of the Board
Interim Independent Non-Executive Chairman of the Board
--
--
Dr. Michele A. M. Holcomb, Ph.D.
Dr. Michele A. M. Holcomb, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Langer (Robert S Jr)
Langer (Robert S Jr)
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Eric Elenko, Ph.D.
Dr. Eric Elenko, Ph.D.
President, Director
President, Director
--
--
Mr. Robert (Rob) Lyne
Mr. Robert (Rob) Lyne
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
Dr. Charles H. Sherwood, Ph.D.
Dr. Charles H. Sherwood, Ph.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kiran Mazumdar-Shaw
Ms. Kiran Mazumdar-Shaw
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sharon Barber-lui
Ms. Sharon Barber-lui
Interim Independent Non-Executive Chairman of the Board
Interim Independent Non-Executive Chairman of the Board
--
--
Dr. Michele A. M. Holcomb, Ph.D.
Dr. Michele A. M. Holcomb, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Langer (Robert S Jr)
Langer (Robert S Jr)
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Eric Elenko, Ph.D.
Dr. Eric Elenko, Ph.D.
President, Director
President, Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: lun., 2 de jun
Actualizado: lun., 2 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Birch Hill Investment Advisors LLC
1.01%
Millennium Management LLC
0.19%
Pentwater Capital Management LP
0.14%
Portolan Capital Management, L.L.C.
0.05%
Other
98.62%
Accionistas
Accionistas
Proporción
Birch Hill Investment Advisors LLC
1.01%
Millennium Management LLC
0.19%
Pentwater Capital Management LP
0.14%
Portolan Capital Management, L.L.C.
0.05%
Other
98.62%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
1.26%
Hedge Fund
0.33%
Investment Advisor/Hedge Fund
0.05%
Other
98.36%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
15
335.52K
1.39%
-63.86K
2025Q1
14
393.56K
1.64%
-4.75K
2024Q4
14
374.87K
1.56%
+317.90K
2024Q3
13
30.04K
0.13%
-317.21K
2024Q2
12
323.23K
1.35%
+280.87K
2024Q1
9
25.15K
0.09%
-3.71K
2023Q4
10
11.40K
0.04%
-82.93K
2023Q3
12
84.27K
0.31%
-16.31K
2023Q2
11
83.51K
0.30%
-16.43K
2023Q1
13
82.93K
0.30%
-317.41K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Birch Hill Investment Advisors LLC
302.00K
1.25%
--
--
Mar 31, 2025
Millennium Management LLC
44.91K
0.19%
-353.00
-0.78%
Mar 31, 2025
Pentwater Capital Management LP
33.56K
0.14%
+9.45K
+39.19%
Mar 31, 2025
Portolan Capital Management, L.L.C.
11.88K
0.05%
+11.88K
--
Mar 31, 2025
Fidelity Management & Research Company LLC
1.28K
0.01%
--
--
May 31, 2025
Geode Capital Management, L.L.C.
770.00
0%
--
--
May 31, 2025
Dimensional Fund Advisors, L.P.
316.00
0%
-208.00
-39.69%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
100.00
0%
--
--
Mar 31, 2025
UBS Financial Services, Inc.
20.00
0%
-1.88K
-98.95%
Mar 31, 2025
Dimensional Fund Advisors, Ltd.
--
0%
-196.00
-100.00%
Jan 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
